Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies

Table 1

Summary of BVA, gain, final VA and mean number of injections in the overall population and subgroups for anti-VEGF and DEX-implant observational studies (BVA: baseline visual acuity, IVI: intravitreal injection.

	Anti-VEGF							DEX-implant
	Number of eyes	BVA (letters)	Mean gain (letters)	Final VA (letters)	Mean follow-up (months)	Mean IVI	Number of eyes	BVA (letters)	Mean gain (letters)	Max VA (letters)	Mean follow-up (months)	Mean IVI
Overall population	6842	57.3	+4.7	62	15.6	5.8	1703	51.5	+9.6	61.2	10.3	1.6
BVA
≤ 50 letters	449	42.4	+4.3	46.7	13	3	363	39.4	+10.5	49.9	9	1.2
50-60 letters	4773	55.7	+5.8	61.7	16.3	5.8	1218	54.1	+9.3	63.7	11.6	1.75
≥ 60 letters	1620	65.3	+3.1	68.3	13.5	6.5	122	68.4	+8.8	76.5	9	1.8
Initial Status
Naive patients	781	56	+5	61	12.3	5.2	176	57.9	+ 12	69.9	10.8	1.9
Non-naïve patients	413	56.9	+ 4.8	61.8	12.1	6.2	801	48.7	+8.6	57.3	9.2	1.4